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Background: Over-expressing VEGF improves function in chronic myocardial ischemia but the mechanism is unknown and the relative role of 
paracrine vs. direct myocardial effects has not been established
Methods: Swine with hibernating myocardium from a chronic LAD occlusion received extracardiac plasmid VEGF165 (500μg) at 4 skeletal muscle 
sites. We assessed flow (microspheres) and function (echo) 4 weeks (n=8) after VEGF165 vs. untreated hibernating myocardium (n=6) and sham 
controls (n=5). Histological analysis was performed to quantify myocyte size and nuclear density. Proliferating cardiomyocytes in the growth phase of 
the cell cycle (Ki-67) and mitosis (phospho-Histone H3, pHH3) were quantified with immunofluorescence.
Results: Extracardiac VEGF165 increased LAD wall thickening from 3.0 ± 0.5 mm in untreated to 5.1 ± 0.6 mm after 4 weeks (p<0.05). Vasodilated 
flow did not change after VEGF (LAD/remote 0.27 ± .03 in untreated vs. 0.25 ± .02 after VEGF165, p-ns). Extracardiac VEGF165 increased Ki-67 and 
pHH3 positive myocytes (Table) in parallel with an increase in myocyte nuclei (713 ± 46 to 827 ± 23 nuclei/mm2, p<0.05) and reversed cellular 
hypertrophy.
Conclusions: These data indicate that extracardiac VEGF165 improves function by increasing myocyte proliferation independently of perfusion. 
The use of peripheral skeletal muscle VEGF165 injection supports a paracrine action and may provide a noninvasive approach to improve viable 
dysfunctional myocardium.
Quantitative Histology / Immunohistochemistry
Hibernating LAD
Sham (n=5) Untreated(n=6) VEGF165(n=8)
LAD ΔWT (ESWT-EDWT) (mm) 6.4 ± 0.5 3.0 ± 0.5* 5.1 ± 0.6†
Myocyte Nuclear Density (number/mm2) 1212 ± 36 713 ± 46* 827 ± 23*†
Ki67+ Myocytes (nuclei/106 myocytes) 284 ± 69 410 ± 82* 675 ± 81*†
pHH3+ Myocytes (nuclei/106 myocytes) 2 ± 2 9 ± 5 126 ± 31*†
Myocyte Diameter (μm) 13.8 ± 0.4 18.4 ± 1.0* 15.8 ±0.4*†
Mean ± SEM, *p<0.05 vs. Sham, †p<0.05 Untreated vs.VEGF165
